Table 1. Baseline characteristics of the patient populations.
| LTS (n = 67) | CAD (n = 52) | ES (n = 28) | ESRD (n = 45) | HC (n = 26) | |
|---|---|---|---|---|---|
| Age (year) | 55.2±9.7 | 48.3±8.6 | 41.2±10.3 | 44.7±10.5 | 35.5±9.3 |
| Male, n (%) | 38 (57) | 25 (48) | 16 (57) | 29 (64) | 8 (30.8) |
| Post-transplant year | 17.1±4.9*, † | 9.2±4.3 # | 0.4±01 | - | - |
| HLA mismatch | 3.1±1.4 | 3.3±1.5 | 3.1±1.9 | - | - |
| Donor (LD / DD), n (%) | 61 / 6 (91 / 9)* | 31 / 21 (60 / 40) † | 28 / 0 (100 / 0) | - | - |
| Immune suppressant regimen | *, † | † | |||
| Tac based triple therapy | 2 (3) | 19 (38) | 21 (75) | - | - |
| CsA based triple therapy | 17 (25) | 13 (26) | 5 (18) | - | - |
| Tac based dual therapy | 5 (8) | 1 (2) | 0 (0) | - | - |
| CsA based dual therapy | 4 (6) | 0 (0) | 0 (0) | - | - |
| AZA+steroid | 5 (8) | 1 (2) | 0 (0) | - | - |
| Tac monotherapy (±steroid) | 3 (5) | 9 (18) | 2 (7) | - | - |
| CsA monotherapy (±steroid) | 31 (46) | 7 (14) | 0 (0) | - | - |
ADPKD, autosomal dominant polycystic kidney disease; AZA, azathioprine; CAD, chronic allograft dysfunction; CsA, cyclosporine; DD, deceased donor; DM, diabetes mellitus; ES, early stable; ESRD, end stage renal disease; GN, glomerulonephritis; HC, healthy control; LD, living donor; LTS, long term stable; MIZ, miroribine; MMF, mycophenolate mofetil; Tac, Tacrolimus; SRL, sirolimus
Tac (or CsA) based triple therapy included Tac (or CsA)+MMF+Steroid or Tac (or CsA)+MIZ+Steroid or Tac (or CsA)+SRL+Steroid
Tac (or CsA) based dual therapy included Tac (or CsA) +AZA, Tac (or CsA) +MMF, Tac (or CsA) +MIZ
* P<0.05 vs. CAD
† P<0.05 vs. ES
# P<0.05 vs. LTS